Evommune stock plunges after Phase 2b atopic dermatitis results disappoint

Evommune Inc. tumbled 27.4% in post-market trading to $9.50 after publishing top-line Phase 2b results for EVO756 in moderate-to-severe atopic dermatitis — a readout the company had pinpointed as its next major clinical milestone for September 2026. The outcome clearly disappointed investors, prompting a sharp de-rating of a stock that was already under pressure following the drug's previous failure in chronic spontaneous urticaria.

The decline compounds an already difficult period for the company. In June 2026, EVO756 failed to achieve the primary endpoint in its Phase 2b chronic spontaneous urticaria trial — the mean change in Urticaria Activity Score at 12 weeks — at any dose studied, leading Evommune to abandon development in that indication entirely. That result had already triggered a William Blair downgrade to Market Perform and weighed on sentiment in the run-up to the atopic dermatitis readout. A pattern of insider sales by senior executives in the weeks surrounding the CSU failure added to investor caution.

The broader U.S. equity market offered no support for the slide, with the S&P 500 essentially flat, the Dow Jones slightly lower, and the Nasdaq barely changed on the day — underscoring that the selling in EVMN was driven solely by company-specific developments. Peers developing treatments for inflammatory conditions, including competitors Aclaris Therapeutics and Upstream Bio, saw no similar catalyst. After-hours volume was elevated compared with recent sessions, reflecting the event's binary nature.

The after-hours price of $9.50 now sits below the stock's previous 52-week low of $10.47, a technically significant break that could invite renewed scrutiny of the company's remaining pipeline as the principal source of long-term value: EVO756 for migraine prophylaxis and EVO301, an IL-18 binding protein fusion protein being developed for atopic dermatitis. Top-line migraine data are not expected until 2027.

This article was generated with the assistance of AI and reviewed by an editor. For more information, please see our Terms & Conditions.